United Therapeutics | UTHR - Cash And Equivalent


United Therapeutics reported $1.8B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Amarin USD 156.51M 12.95M Sep/2026
Ardelyx USD 31.21M 36.79M Mar/2026
Baxter International USD 1.98B 175M Sep/2026
Bayer EUR 4.29B 1.44B Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Biogen USD 1.3B 18.9M Sep/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Gilead Sciences USD 3.18B 4.45B Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Insmed USD 396.56M 148.2M Sep/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
J&J USD 16.91B 3.51B Sep/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Moderna USD 1.72B 185M Jun/2026
Omeros USD 1.9M 2.36M Jun/2025
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 508.89M 540.99M Sep/2026
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
United Therapeutics USD 1.8B 523.5M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026